Datasets
Buyer room
ANERVEA.AIManage supplier listing
Anervea (AlfaTRx / Anervea.AI) — Payer policy and market-access intelligence for BioPharma: formulary decisions, reimbursement trends, payer pricing benchmarks, rebate pressure signals, and NLP-derived stakeholder/win-loss analysis from tender documents and formulary data, aggregated across clients' engagements.. Mid-size BioPharma market-access consultancy/platform: 51 employees, Philadelphia based, no disclosed funding round, serving BioPharma clients including at least one cited 'Global BioPharma Company' case study.. Use cases: Pharma payer-pricing and formulary benchmarking, launch/acces…
Payer policy and market-access intelligence for BioPharma: formulary decisions, reimbursement trends, payer pricing benchmarks, rebate pressure signals, and NLP-derived stakeholder/win-loss analysis from tender documents and formulary data, aggregated across clients' engagements.
From 5 yearsCoverage Health CareAsset class Equities
Sample, licence terms, pricing and eval results when Anervea publishes them. Until then, discover alternatives today with a 7-day trial.
Start 7-day trial →What buyers ask about Anervea, answered from this page.
Anervea (AlfaTRx / Anervea.AI) — Payer policy and market-access intelligence for BioPharma: formulary decisions, reimbursement trends, payer pricing benchmarks, rebate pressure signals, and NLP-derived stakeholder/win-loss analysis from tender documents and formulary data, aggregated across clients' engagements.. Mid-size BioPharma market-access consultancy/platform: 51 employees, Philadelphia based, no disclosed funding round, serving BioPharma clients including at least one cited 'Global BioPharma Company' case study.. Use cases: Pharma payer-pricing and formulary benchmarking, launch/acces…
Anervea offers (Alternative, Reference) — Est. covers formulary/reimbursement data across multiple major payers and therapeutic areas per client engagement; exact record count not published -- scale likely in the tens of thousands of formulary/tender data points given the described cross-payer benchmarking scope..
Pharma payer-pricing and formulary benchmarking, launch/access strategy planning, competitive win-loss analysis for market access teams, training ground truth for an NLP model on tender/formulary document classification.
The data is with 5 years of history.
Coverage spans US; Pharmaceuticals; alternative, reference; equities.
Anervea has not added their own details yet. Not yet on file: